ArticleHeliyon2023
Size control of precipitated particles of amino acids using a bubble column evaporator.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The precipitation of five amino acids: DL-alanine, L-arginine, L-leucine, DL-methionine and L-tyrosine was studied at their solubility limits and isoelectric point by using a bubble column evaporator (BCE). The precipitation of amino acids via a bubble column evaporator and a standard stirring method were compared via turbidity measurements. Particle size, zeta potential and polydispersity index (PDI) were also measured using a Malvern Zeta-sizer and the particle morphology was examined using Scanning Electron Microscopy (SEM). The novel BCE process emerges as a much more effective method than precipitation by standard stirring methods. Better control of fine particle size and growth rates is achieved. The amino acids in zwitterionic form exhibit the same unexplained bubble coalescence inhibition phenomenon as do common salts. This suggests obvious applications in flotation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.